The Food and Drug Administration said Saturday it has awarded emergency use authorization to Regeneron Pharmaceuticals to treat COVID-19 in certain individuals.It’s approved to treat mild and moderate COVID-19 for high-risk adults and pediatric patients ages 12 and older, the FDA said.The treatment involving casirivimab and imdevimab was shown to reduce hospitalization or emergency room visits for high-risk patients.”Authorizing these monoclonal antibody therapies may help outpatients…

… Continue Reading at: www.wesh.com [source]